Gene therapy vs. standard drugs: Head-to-Head bladder cancer battle
NCT ID NCT06929286
Summary
This study compares different FDA-approved treatments for bladder cancer that hasn't spread into the muscle wall. It tests a newer gene therapy drug called nadofaragene firadenovec against several standard treatment options. The trial is for adults whose cancer returned after initial BCG immunotherapy. Researchers want to see which treatment best prevents cancer from coming back or getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.